News & Updates
Filter by Specialty:
Second primary melanoma tied to better survival than single primary lesion
Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.
Second primary melanoma tied to better survival than single primary lesion
06 May 2023Immune-related AEs predict survival in cancer patients on ICI
Developing cutaneous immune-related adverse events (cirAEs) among advanced cancer patients on immune checkpoint inhibitor (ICI) appears to be a sign of longer overall survival, particularly in those with melanoma, suggests a recent study.
Immune-related AEs predict survival in cancer patients on ICI
05 May 2023Tralokinumab a promising treatment option in young people with moderate-to-severe AD
Targeting interleukin (IL)-13 with tralokinumab monotherapy helps reduce disease activity in adolescents with moderate-to-severe atopic dermatitis (AD) with a low frequency of conjunctivitis throughout the treatment period, according to data from the phase III ECZTRA 6 trial.
Tralokinumab a promising treatment option in young people with moderate-to-severe AD
29 Apr 2023SG: Acne in youths managed suboptimally in primary care
The prescribing patterns for acne among local primary care physicians appear to deviate from clinical practice guidelines used to achieve optimal outcomes for young people, as shown in a Singapore study.
SG: Acne in youths managed suboptimally in primary care
19 Apr 2023Apremilast safe, effective in moderate-to-severe genital psoriasis
Treatment with apremilast demonstrates consistent efficacy in genital psoriasis and overall psoriasis symptoms at 16 weeks irrespective of body surface area (BSA) at baseline, suggest the results of the phase III DISCREET trial presented at the recent AAD 2023.
Apremilast safe, effective in moderate-to-severe genital psoriasis
13 Apr 2023Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
Treatment with lebrikizumab with or without topical corticosteroids (TCS) results in clinical improvement among adolescents with moderate-to-severe atopic dermatitis (AD), according to a study presented at the recent AAD 2023.